Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern

From National Research Council Canada

Download	View final version: Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern (PDF, 1.4 MiB) View supplementary information: Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern (PDF, 1.1 MiB)
DOI	Resolve DOI: https://doi.org/10.1038/s41541-022-00540-7
Author	Search for: Akache, Bassel¹ORCID identifier: https://orcid.org/0000-0002-5377-7193; Search for: Renner, Tyler M.¹ORCID identifier: https://orcid.org/0000-0002-9196-5021; Search for: Stuible, Matthew¹; Search for: Rohani, Nazanin¹ORCID identifier: https://orcid.org/0000-0003-3916-6115; Search for: Cepero-Donates, Yuneivy¹; Search for: Deschatelets, Lise¹; Search for: Dudani, Renu¹; Search for: Harrison, Blair A.¹; Search for: Gervais, Christian¹; Search for: Hill, Jennifer J.¹; Search for: Hemraz, Usha D.²; Search for: Lam, Edmond²; Search for: Régnier, Sophie²; Search for: Lenferink, Anne E. G.¹; Search for: Durocher, Yves¹; Search for: McCluskie, Michael J.¹ORCID identifier: https://orcid.org/0000-0001-5538-1363
Affiliation	National Research Council Canada. Human Health Therapeutics National Research Council Canada. Aquatic and Crop Resource Development
Format	Text, Article
Subject	protein vaccines; viral infections
Abstract	Using our strongly immunogenic SmT1 SARS-CoV-2 spike antigen platform, we developed antigens based on the Beta & Delta variants of concern (VOC). These antigens elicited higher neutralizing antibody activity to the corresponding variant than comparable vaccine formulations based on the original reference strain, while a multivalent vaccine generated cross-neutralizing activity in all three variants. This suggests that while current vaccines may be effective at reducing severe disease to existing VOC, variant-specific antigens, whether in a mono- or multivalent vaccine, may be required to induce optimal immune responses and reduce infection against arising variants.
Publication date	2022-10-12
Publisher	Springer Nature Sealy Institute for Vaccine Sciences
Licence	Creative Commons Attribution 4.0 International (CC BY 4.0) https://creativecommons.org/licenses/by/4.0/
In	npj Vaccines 7, no. 1, 118 (12 October 2022): 1–7.
Language	English
Peer reviewed	Yes
Export citation	Export as RIS
Report a correction	Report a correction (opens in a new tab)
Record identifier	36693013-f815-4518-81d7-ef0e488d6b0a
Record created	2023-06-06
Record modified	2023-06-06

Date modified:: 2026-01-13